Bo Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bo Shen has a total of 396 co-authors. Here are the top co-authors by number of shared publications:
Xiaoyue Du
Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Jiangsu, Nanjing, China
16 shared publicationsShaodi Wen
Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
15 shared publicationsGuoren Zhou
Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Jiangsu, Nanjing, China
8 shared publicationsWei Zhu
Jiangsu University
8 shared publicationsBanzhou Pan
Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
7 shared publicationsJingwei Xia
Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing China
7 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Scilight Press Pty Ltd in Nano-electrochemistry & Nano-photochemistry
- Vol. 2 (4) , 24
Cross-Adsorbate Scaling, Interpretable Machine Learning, and Adsorption Trade-Offs across M–N4–C Sites
Metal–nitrogen–carbon sites provide a chemically diverse platform for tuning adsorbate binding, yet the relationships among different C1 adsorption probes remain incompletely resolved. Here, density functional theory and interpretable machine learning are combined across a 35-metal M–N4–C chemical space to examine *COOH, *CO, and *CHO adsorption as complementary probes. The adsorption landscapes are strongly adsorbate dependent, but *COOH and *CHO exhibit a cross-adsorbate scaling relation (R2 = 0.919), consistent with similar metal-dependent stabilization across much of the series. In contrast, relationships involving *CO show larger residual variation. Gradient-boosting models evaluated by nested out-of-fold prediction recover descriptor-based signal for all three targets; *CO is predicted most accurately (R2 = 0.851; MAE = 0.272 eV), whereas *COOH and *CHO show moderate predictability. Permutation importance, direct DFT correlations, and out-of-fold SHAP analysis identify d-electron count as a recurring organizer of *COOH and *CO adsorption and periodic group as a recurring organizer of *CO and *CHO adsorption. Robust regression highlights Os, Ru, and Re as pronounced *COOH–*CO scaling deviations, while Y departs strongly from the tighter *COOH–*CHO relation. Separate Pareto analyses highlight Y, Os, and Ti under different two-objective adsorption trade-offs. The combined analysis distinguishes shared adsorption trends from adsorbate-specific behavior and identifies chemically informative sites for subsequent mechanistic study.
- 3 November 2026
- Published by Scilight Press Pty Ltd in Nano-electrochemistry & Nano-photochemistry
- Vol. 2 (4) , 24
Open AccessCross-Adsorbate Scaling, Interpretable Machine Learning, and Adsorption Trade-Offs across M–N4–C Sites
Metal–nitrogen–carbon sites provide a chemically diverse platform for tuning adsorbate binding, yet the relationships among different C1 adsorption probes remain incompletely resolved. Here, density functional theory and interpretable machine learning are combined across a 35-metal M–N4–C chemical space to examine *COOH, *CO, and *CHO adsorption as complementary probes. The adsorption landscapes are strongly adsorbate dependent, but *COOH and *CHO exhibit a cross-adsorbate scaling relation (R2 = 0.919), consistent with similar metal-dependent stabilization across much of the series. In contrast, relationships involving *CO show larger residual variation. Gradient-boosting models evaluated by nested out-of-fold prediction recover descriptor-based signal for all three targets; *CO is predicted most accurately (R2 = 0.851; MAE = 0.272 eV), whereas *COOH and *CHO show moderate predictability. Permutation importance, direct DFT correlations, and out-of-fold SHAP analysis identify d-electron count as a recurring organizer of *COOH and *CO adsorption and periodic group as a recurring organizer of *CO and *CHO adsorption. Robust regression highlights Os, Ru, and Re as pronounced *COOH–*CO scaling deviations, while Y departs strongly from the tighter *COOH–*CHO relation. Separate Pareto analyses highlight Y, Os, and Ti under different two-objective adsorption trade-offs. The combined analysis distinguishes shared adsorption trends from adsorbate-specific behavior and identifies chemically informative sites for subsequent mechanistic study.
- Open Access
- 22 October 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
Tetrandrine stabilizes NCOA4 to promote ferritinophagy-mediated ferroptosis and enhance antitumor immunity in NSCLC
Background: Natural products are an important source of anticancer agents. Tetrandrine is a natural bisbenzylisoquinoline alkaloid, but how it regulates ferritinophagy and ferroptosis in non-small cell lung cancer (NSCLC) and affects antitumor immunity remains unclear. This study investigated its mechanism of action and potential for combination with anti-PD-1 therapy. Methods: Antitumor activity was evaluated in NSCLC cell lines, patient-derived lung adenocarcinoma organoids, and mouse tumor models. Proteomic and transcriptomic analyses, pharmacological interventions, and gene overexpression and knockdown experiments were used to investigate ferritinophagy and ferroptosis. Target-binding, protein stability, and ubiquitination assays examined the regulation of nuclear receptor coactivator 4 (NCOA4). Co-immunoprecipitation, proximity ligation assays, structural prediction, and truncation and deletion analyses characterized the NCOA4–TAX1BP1 interaction. Tumor cell–PBMC co-cultures and LLC and CMT167 syngeneic tumor models were used to assess T-cell responses and combination treatment. Results: Tetrandrine reduced NSCLC cell and organoid viability and increased intracellular Fe²⁺ accumulation and lipid peroxidation. Ferroptosis inhibitors partially attenuated these effects. Tetrandrine promoted lysosomal ferritin degradation and directly bound NCOA4, increasing its stability. HERC2 downregulation and reduced K48-linked NCOA4 ubiquitination contributed to this stabilization. Tetrandrine also enhanced the NCOA4–TAX1BP1 interaction. Deletion of NCOA4 residues 540–560 weakened this interaction and attenuated tetrandrine-induced iron accumulation, lipid peroxidation, and growth inhibition. In co-culture and animal models, tetrandrine increased markers of CD8⁺ T-cell activation or effector function, with some effects attenuated by iron chelation. Combined tetrandrine and anti-PD-1 treatment produced greater tumor suppression than either monotherapy in both syngeneic models. Conclusions: Tetrandrine stabilizes NCOA4 and enhances its interaction with TAX1BP1, promoting ferritinophagy and subsequent ferroptosis. Its antitumor activity is accompanied by enhanced CD8⁺ T-cell effector responses in the tumor microenvironment and improved efficacy of anti-PD-1 treatment, supporting further investigation of tetrandrine for NSCLC therapy.
- 22 October 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
Open AccessTetrandrine stabilizes NCOA4 to promote ferritinophagy-mediated ferroptosis and enhance antitumor immunity in NSCLC
Background: Natural products are an important source of anticancer agents. Tetrandrine is a natural bisbenzylisoquinoline alkaloid, but how it regulates ferritinophagy and ferroptosis in non-small cell lung cancer (NSCLC) and affects antitumor immunity remains unclear. This study investigated its mechanism of action and potential for combination with anti-PD-1 therapy. Methods: Antitumor activity was evaluated in NSCLC cell lines, patient-derived lung adenocarcinoma organoids, and mouse tumor models. Proteomic and transcriptomic analyses, pharmacological interventions, and gene overexpression and knockdown experiments were used to investigate ferritinophagy and ferroptosis. Target-binding, protein stability, and ubiquitination assays examined the regulation of nuclear receptor coactivator 4 (NCOA4). Co-immunoprecipitation, proximity ligation assays, structural prediction, and truncation and deletion analyses characterized the NCOA4–TAX1BP1 interaction. Tumor cell–PBMC co-cultures and LLC and CMT167 syngeneic tumor models were used to assess T-cell responses and combination treatment. Results: Tetrandrine reduced NSCLC cell and organoid viability and increased intracellular Fe²⁺ accumulation and lipid peroxidation. Ferroptosis inhibitors partially attenuated these effects. Tetrandrine promoted lysosomal ferritin degradation and directly bound NCOA4, increasing its stability. HERC2 downregulation and reduced K48-linked NCOA4 ubiquitination contributed to this stabilization. Tetrandrine also enhanced the NCOA4–TAX1BP1 interaction. Deletion of NCOA4 residues 540–560 weakened this interaction and attenuated tetrandrine-induced iron accumulation, lipid peroxidation, and growth inhibition. In co-culture and animal models, tetrandrine increased markers of CD8⁺ T-cell activation or effector function, with some effects attenuated by iron chelation. Combined tetrandrine and anti-PD-1 treatment produced greater tumor suppression than either monotherapy in both syngeneic models. Conclusions: Tetrandrine stabilizes NCOA4 and enhances its interaction with TAX1BP1, promoting ferritinophagy and subsequent ferroptosis. Its antitumor activity is accompanied by enhanced CD8⁺ T-cell effector responses in the tumor microenvironment and improved efficacy of anti-PD-1 treatment, supporting further investigation of tetrandrine for NSCLC therapy.
- Open Access
- 12 August 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (8) , e014673
PGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma
Background: Acquired resistance limits the durability of programmed cell death protein-1 (PD-1) blockade in lung adenocarcinoma, yet the tumor-intrinsic programs and immune circuits that drive acquired resistance relapse remain poorly defined. The purpose of this study was to identify tumor-intrinsic mediators of acquired resistance and determine how they remodel antitumor immunity. Methods: An orthotopic bioluminescence-tracked Lewis lung carcinoma (LLC1) lung adenocarcinoma model was established in immunocompetent mice treated with anti-PD-1. Tumor-intrinsic regulators were identified by an in vivo genome-wide CRISPR loss-of-function screen and validated using inducible tetracycline-off knockdown. Prostaglandin E2 (PGE2) signaling was interrogated through tumor-cell Ptgs2 knockdown/deletion, 16,16-dimethyl PGE2 administration, selective EP2/EP4 antagonists, and celecoxib treatment. Natural killer (NK)-cell function was analyzed by flow cytometry, immunofluorescence, RNA sequencing, cAMP measurement, calcium flux assays, mouse and human NK-cell co-culture cytotoxicity assays, and NK-cell adoptive transfer. Celecoxib was used to evaluate the therapeutic potential of pharmacologic PGE2 blockade in vivo. Public immunotherapy datasets were analyzed to assess the clinical relevance of PTGS2. Results: The orthotopic LLC1 model captured key features of heterogeneous anti-PD-1 responses, including relapse after initial regression. The CRISPR screen identified Ptgs2 as a key driver of acquired resistance. Tumor-derived PGE2 progressively increased in resistant tumors, and its genetic silencing overcame resistance by restoring NK-cell infiltration and function. Mechanistically, PGE2 signaled through EP2/EP4 receptors to elevate cAMP and induce CREM, thereby suppressing NK-cell cytotoxicity and cytokine production. This axis was validated in human NK cells. Pharmacologic inhibition of cyclooxygenase-2 with celecoxib reversed acquired resistance, an effect abrogated by NK-cell depletion. Conclusions: Tumor-derived PGE2 is an important contributor to acquired resistance to PD-1 blockade in lung adenocarcinoma. Therapeutic disruption of the EP2/EP4–cAMP–CREM axis restores NK-cell function and overcomes acquired resistance.
- 12 August 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (8) , e014673
Open AccessPGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma
Background: Acquired resistance limits the durability of programmed cell death protein-1 (PD-1) blockade in lung adenocarcinoma, yet the tumor-intrinsic programs and immune circuits that drive acquired resistance relapse remain poorly defined. The purpose of this study was to identify tumor-intrinsic mediators of acquired resistance and determine how they remodel antitumor immunity. Methods: An orthotopic bioluminescence-tracked Lewis lung carcinoma (LLC1) lung adenocarcinoma model was established in immunocompetent mice treated with anti-PD-1. Tumor-intrinsic regulators were identified by an in vivo genome-wide CRISPR loss-of-function screen and validated using inducible tetracycline-off knockdown. Prostaglandin E2 (PGE2) signaling was interrogated through tumor-cell Ptgs2 knockdown/deletion, 16,16-dimethyl PGE2 administration, selective EP2/EP4 antagonists, and celecoxib treatment. Natural killer (NK)-cell function was analyzed by flow cytometry, immunofluorescence, RNA sequencing, cAMP measurement, calcium flux assays, mouse and human NK-cell co-culture cytotoxicity assays, and NK-cell adoptive transfer. Celecoxib was used to evaluate the therapeutic potential of pharmacologic PGE2 blockade in vivo. Public immunotherapy datasets were analyzed to assess the clinical relevance of PTGS2. Results: The orthotopic LLC1 model captured key features of heterogeneous anti-PD-1 responses, including relapse after initial regression. The CRISPR screen identified Ptgs2 as a key driver of acquired resistance. Tumor-derived PGE2 progressively increased in resistant tumors, and its genetic silencing overcame resistance by restoring NK-cell infiltration and function. Mechanistically, PGE2 signaled through EP2/EP4 receptors to elevate cAMP and induce CREM, thereby suppressing NK-cell cytotoxicity and cytokine production. This axis was validated in human NK cells. Pharmacologic inhibition of cyclooxygenase-2 with celecoxib reversed acquired resistance, an effect abrogated by NK-cell depletion. Conclusions: Tumor-derived PGE2 is an important contributor to acquired resistance to PD-1 blockade in lung adenocarcinoma. Therapeutic disruption of the EP2/EP4–cAMP–CREM axis restores NK-cell function and overcomes acquired resistance.
- Open Access
- 19 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
Progression-free survival (PFS) with first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors remains suboptimal in EGFR L858R-mutated advanced non-small-cell lung cancer (NSCLC), highlighting a need for strategies to delay resistance. This single-arm, phase II study (FIRM; ChiCTR2200060897) evaluates first-line double-dose firmonertinib (160 mg/day) in adults with L858R-mutated locally advanced or metastatic NSCLC. With a median follow-up of 27.5 months in 33 patients, primary endpoint was a median PFS of 21.1 months. Secondary endpoints include an unreached median overall survival, an objective response rate of 75.8%, a disease control rate of 90.9%, and an 18-month PFS rate of 63.1%. Grade ≥3 treatment-emergent adverse events occur in 6.1% of patients. Baseline circulating tumor DNA (ctDNA) variant allele frequency predicts ctDNA clearance at cycle 3 day 1, which correlates with longer PFS. Double-dose firmonertinib shows promising efficacy and tolerability, supporting its preliminary potential as first-line treatment for EGFR L858R-mutated advanced NSCLC.
- 19 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDouble-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
Progression-free survival (PFS) with first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors remains suboptimal in EGFR L858R-mutated advanced non-small-cell lung cancer (NSCLC), highlighting a need for strategies to delay resistance. This single-arm, phase II study (FIRM; ChiCTR2200060897) evaluates first-line double-dose firmonertinib (160 mg/day) in adults with L858R-mutated locally advanced or metastatic NSCLC. With a median follow-up of 27.5 months in 33 patients, primary endpoint was a median PFS of 21.1 months. Secondary endpoints include an unreached median overall survival, an objective response rate of 75.8%, a disease control rate of 90.9%, and an 18-month PFS rate of 63.1%. Grade ≥3 treatment-emergent adverse events occur in 6.1% of patients. Baseline circulating tumor DNA (ctDNA) variant allele frequency predicts ctDNA clearance at cycle 3 day 1, which correlates with longer PFS. Double-dose firmonertinib shows promising efficacy and tolerability, supporting its preliminary potential as first-line treatment for EGFR L858R-mutated advanced NSCLC.
- Open Access
- 20 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Suppressing the OTUD7A/KDM5B/GABPA axis enhances the sensitivity of cisplatin through inducing ferroptosis in KRAS-mutant LUAD
KRAS-mutant lung adenocarcinoma (LUAD), due to its evolution of more complex antioxidant metabolic mechanisms, exhibits poorer sensitivity to conventional platinum-based drugs compared to other types of LUAD. Ferroptosis, as a means of inducing cell death in cancer therapy, shows unique features and potential therapeutic effects compared to the conventional form of apoptosis, which is frequently obstructed by drug resistance. In human KRAS-mutant LUAD cell lines and mouse models, we found that the deubiquitinase OTU deubiquitinase 7A (OTUD7A) precisely regulates the lysine demethylase 5B (KDM5B). Inhibition of KDM5B expression increases the H4K20me3 level, which in turn downregulates the expression of transcription factor GABPA associated with mitochondrial function, ultimately promoting the production of more Reactive Oxygen Species (ROS) by mitochondria and inducing ferroptosis. Additionally, in in vivo organoid models, cisplatin (CDDP) induced ferroptosis combined with GABPA inhibition demonstrated superior anticancer effects compared to conventional platinum-based drugs. This research identifies new targets and regulatory networks that hold promise for developing ferroptosis-based therapies for KRAS-mutant LUAD.
- 20 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessSuppressing the OTUD7A/KDM5B/GABPA axis enhances the sensitivity of cisplatin through inducing ferroptosis in KRAS-mutant LUAD
KRAS-mutant lung adenocarcinoma (LUAD), due to its evolution of more complex antioxidant metabolic mechanisms, exhibits poorer sensitivity to conventional platinum-based drugs compared to other types of LUAD. Ferroptosis, as a means of inducing cell death in cancer therapy, shows unique features and potential therapeutic effects compared to the conventional form of apoptosis, which is frequently obstructed by drug resistance. In human KRAS-mutant LUAD cell lines and mouse models, we found that the deubiquitinase OTU deubiquitinase 7A (OTUD7A) precisely regulates the lysine demethylase 5B (KDM5B). Inhibition of KDM5B expression increases the H4K20me3 level, which in turn downregulates the expression of transcription factor GABPA associated with mitochondrial function, ultimately promoting the production of more Reactive Oxygen Species (ROS) by mitochondria and inducing ferroptosis. Additionally, in in vivo organoid models, cisplatin (CDDP) induced ferroptosis combined with GABPA inhibition demonstrated superior anticancer effects compared to conventional platinum-based drugs. This research identifies new targets and regulatory networks that hold promise for developing ferroptosis-based therapies for KRAS-mutant LUAD.
- Open Access
- 19 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1735479
SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
Background: Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of T H 1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results: Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8 + T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8 + T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion: our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.
- 19 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1735479
Open AccessSAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
Background: Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of T H 1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results: Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8 + T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8 + T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion: our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.
- Open Access
- 10 October 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (10) , e010416
ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer
Background: Metastatic recurrence poses a significant challenge in cancer treatment, impacting patient survival and prognosis. Understanding the biological mechanisms behind it is essential for improving treatment strategies and patient outcomes. Lung cancer, the leading cause of cancer-related deaths, is a focus of research for treatment and prognosis. This study specifically targets stage III non-small cell lung cancer (NSCLC) patients following surgery due to their high recurrence variability. Methods: To delve into the mechanisms of metastatic recurrence in stage III NSCLC patients, we used a comprehensive experimental approach. Long-term follow-up of postoperative patients was combined with single-cell sequencing to uncover tumor microenvironment changes. In vivo and in vitro experiments, including tissue cytometry analysis, real-time PCR, western blotting, gene silencing, cell co-culture, flow cytometry, and chromatin immunoprecipitation-quantitative PCR, were conducted to investigate ALCAM-related gene regulation. Tissue samples and clinical data were collected from stage III NSCLC patients who underwent lung cancer resection between August 2018 and July 2021. Results: Analysis revealed distinct epithelial gene expression patterns between recurrence and non-recurrence groups, highlighting the reduced interaction between ALCAM ligand on epithelial cells and CD6 receptor on T cells. Lower ALCAM levels intensified an immunosuppressive state, halting cell cycle progression and promoting tumor proliferation and migration, linked to metastatic recurrence. The transcription factor MYB was identified as a key ALCAM regulator, shedding light on its impact on tumor advancement. Reduced ALCAM expression correlated with poorer prognosis, offering insights into NSCLC recurrence mechanisms. Conclusions: Our study underscores the pivotal role of the ALCAM-CD6 axis in metastatic recurrence of stage III NSCLC. ALCAM regulation not only influences immune-tumor cell interactions but also drives tumor cell proliferation and migration by affecting the cell cycle. This finding presents a promising target for NSCLC treatment and aids in assessing patient prognosis effectively.
- 10 October 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (10) , e010416
Open AccessALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer
Background: Metastatic recurrence poses a significant challenge in cancer treatment, impacting patient survival and prognosis. Understanding the biological mechanisms behind it is essential for improving treatment strategies and patient outcomes. Lung cancer, the leading cause of cancer-related deaths, is a focus of research for treatment and prognosis. This study specifically targets stage III non-small cell lung cancer (NSCLC) patients following surgery due to their high recurrence variability. Methods: To delve into the mechanisms of metastatic recurrence in stage III NSCLC patients, we used a comprehensive experimental approach. Long-term follow-up of postoperative patients was combined with single-cell sequencing to uncover tumor microenvironment changes. In vivo and in vitro experiments, including tissue cytometry analysis, real-time PCR, western blotting, gene silencing, cell co-culture, flow cytometry, and chromatin immunoprecipitation-quantitative PCR, were conducted to investigate ALCAM-related gene regulation. Tissue samples and clinical data were collected from stage III NSCLC patients who underwent lung cancer resection between August 2018 and July 2021. Results: Analysis revealed distinct epithelial gene expression patterns between recurrence and non-recurrence groups, highlighting the reduced interaction between ALCAM ligand on epithelial cells and CD6 receptor on T cells. Lower ALCAM levels intensified an immunosuppressive state, halting cell cycle progression and promoting tumor proliferation and migration, linked to metastatic recurrence. The transcription factor MYB was identified as a key ALCAM regulator, shedding light on its impact on tumor advancement. Reduced ALCAM expression correlated with poorer prognosis, offering insights into NSCLC recurrence mechanisms. Conclusions: Our study underscores the pivotal role of the ALCAM-CD6 axis in metastatic recurrence of stage III NSCLC. ALCAM regulation not only influences immune-tumor cell interactions but also drives tumor cell proliferation and migration by affecting the cell cycle. This finding presents a promising target for NSCLC treatment and aids in assessing patient prognosis effectively.
- Open Access
- 1 March 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (3) , 940-962
Identification and validation of crotonylation-related diagnostic markers for lung adenocarcinoma via weighted correlation network analysis and machine learning
Background: Lung adenocarcinoma (LUAD) is one of the most common tumors in terms of incidence and mortality worldwide. Posttranslational modifications, including crotonylation, play a crucial role in various biological processes and diseases. However, the role of crotonylation in LUAD remains unclear. Our research focuses on identifying key genes in LUAD that are linked to crotonylation and prognosis. We also aim to clarify their role in the LUAD microenvironment to advance clinical translation of related targets. Methods: We used RNA-sequencing data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database to identify differentially expressed genes (DEGs) related to crotonylation in LUAD. Weighted correlation network analysis (WGCNA) was applied to construct gene networks, and hub genes were identified using protein-protein interaction (PPI) analysis. The prognostic value of hub genes was assessed using Kaplan-Meier plots, and the correlation with immune infiltration was analyzed via Tumor Immune Estimation Resource (TIMER) and other algorithms. We then verified these genes through clinical samples and confirmed the role of MMACHC in LUAD. Results: We identified GAPDH, SLC25A13, MMACHC, and HDAC1 as potential crotonylation-related biomarkers for LUAD. These genes were found to be overexpressed in LUAD and were associated with poor prognosis. They also showed significant correlations with immune cell infiltration and immune-inflammatory pathways. Functional experiments confirmed that MMACHC knockdown inhibited cell proliferation and migration, induced apoptosis, and enhanced the efficacy of immunotherapy in LUAD. Conclusions: Our study suggests that crotonylation-related genes, particularly MMACHC, may serve as novel therapeutic targets and diagnostic markers for LUAD.
- 1 March 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (3) , 940-962
Open AccessIdentification and validation of crotonylation-related diagnostic markers for lung adenocarcinoma via weighted correlation network analysis and machine learning
Background: Lung adenocarcinoma (LUAD) is one of the most common tumors in terms of incidence and mortality worldwide. Posttranslational modifications, including crotonylation, play a crucial role in various biological processes and diseases. However, the role of crotonylation in LUAD remains unclear. Our research focuses on identifying key genes in LUAD that are linked to crotonylation and prognosis. We also aim to clarify their role in the LUAD microenvironment to advance clinical translation of related targets. Methods: We used RNA-sequencing data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database to identify differentially expressed genes (DEGs) related to crotonylation in LUAD. Weighted correlation network analysis (WGCNA) was applied to construct gene networks, and hub genes were identified using protein-protein interaction (PPI) analysis. The prognostic value of hub genes was assessed using Kaplan-Meier plots, and the correlation with immune infiltration was analyzed via Tumor Immune Estimation Resource (TIMER) and other algorithms. We then verified these genes through clinical samples and confirmed the role of MMACHC in LUAD. Results: We identified GAPDH, SLC25A13, MMACHC, and HDAC1 as potential crotonylation-related biomarkers for LUAD. These genes were found to be overexpressed in LUAD and were associated with poor prognosis. They also showed significant correlations with immune cell infiltration and immune-inflammatory pathways. Functional experiments confirmed that MMACHC knockdown inhibited cell proliferation and migration, induced apoptosis, and enhanced the efficacy of immunotherapy in LUAD. Conclusions: Our study suggests that crotonylation-related genes, particularly MMACHC, may serve as novel therapeutic targets and diagnostic markers for LUAD.
- Open Access
- 20 February 2025
- Vol. 28 (2) , 105-113
[Exploration of the Predictive Value of Peripheral Blood-related Indicators for EGFR Mutations and Prognosis in Non-small Cell Lung Cancer Using Machine Learning].
Epidermal growth factor receptor (EGFR) sensitive mutation is one of the effective targets of targeted therapy for non-small cell lung cancer (NSCLC). However, due to the difficulty of obtaining some primary tissues and the economic factors in some underdeveloped areas, some patients cannot undergo traditional genetic testing. The aim of this study is to establish a machine learning (ML) model using non-invasive peripheral blood markers to explore the biomarkers closely related to EGFR mutation status in NSCLC and evaluate their potential prognostic value. 2642 lung cancer patients who visited Jiangsu Cancer Hospital from November 2016 to May 2023 were retrospectively enrolled and finally 175 NSCLC patients with complete follow-up data were included in the study. The ML model was constructed based on peripheral blood indicators and divided into training set and test set according to the ratio of 8:2. Unsupervised learning algorithms were used for clustering blood features and mutual information method for feature selection, and an ensemble learning algorithm based on Shapley value was designed to calculate the contribution of each feature to the model prediction result. The receiver operating characteristic (ROC) curve was used to evaluate the predictive ability of the model. Through the feature extraction and contribution analysis of the predictive results of the interpretable ML model based on the Shapley value, the top ten indicators with the highest contribution were: pathological type, phosphorus, eosinophils, monocyte count, activated partial thromboplastin time, potassium, total bilirubin, sodium, eosinophil percentage, and total cholesterol. The area under the curve (AUC) of the model was 0.80. In addition, patients with hyponatremia and squamous cell carcinoma group had a poor prognosis (P<0.05). The interpretable model constructed in this study provides a new approach for the prediction of EGFR mutation status in NSCLC patients, which provides a scientific basis for the diagnosis and treatment of patients who cannot undergo genetic testing.
- 20 February 2025
- Vol. 28 (2) , 105-113
Open Access[Exploration of the Predictive Value of Peripheral Blood-related Indicators for EGFR Mutations and Prognosis in Non-small Cell Lung Cancer Using Machine Learning].
Epidermal growth factor receptor (EGFR) sensitive mutation is one of the effective targets of targeted therapy for non-small cell lung cancer (NSCLC). However, due to the difficulty of obtaining some primary tissues and the economic factors in some underdeveloped areas, some patients cannot undergo traditional genetic testing. The aim of this study is to establish a machine learning (ML) model using non-invasive peripheral blood markers to explore the biomarkers closely related to EGFR mutation status in NSCLC and evaluate their potential prognostic value. 2642 lung cancer patients who visited Jiangsu Cancer Hospital from November 2016 to May 2023 were retrospectively enrolled and finally 175 NSCLC patients with complete follow-up data were included in the study. The ML model was constructed based on peripheral blood indicators and divided into training set and test set according to the ratio of 8:2. Unsupervised learning algorithms were used for clustering blood features and mutual information method for feature selection, and an ensemble learning algorithm based on Shapley value was designed to calculate the contribution of each feature to the model prediction result. The receiver operating characteristic (ROC) curve was used to evaluate the predictive ability of the model. Through the feature extraction and contribution analysis of the predictive results of the interpretable ML model based on the Shapley value, the top ten indicators with the highest contribution were: pathological type, phosphorus, eosinophils, monocyte count, activated partial thromboplastin time, potassium, total bilirubin, sodium, eosinophil percentage, and total cholesterol. The area under the curve (AUC) of the model was 0.80. In addition, patients with hyponatremia and squamous cell carcinoma group had a poor prognosis (P<0.05). The interpretable model constructed in this study provides a new approach for the prediction of EGFR mutation status in NSCLC patients, which provides a scientific basis for the diagnosis and treatment of patients who cannot undergo genetic testing.
- Top Cited Papers
- 4 February 2025
- Published by Elsevier in Cell Metabolism
- Vol. 37 (4) , 806-823.e6
Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses
- 4 February 2025
- Published by Elsevier in Cell Metabolism
- Vol. 37 (4) , 806-823.e6
Top Cited PapersInterplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses